Top

International Journal of Clinical Oncology

Published in:

01-02-2019 | Original Article

Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population

Authors: Xu Liu, Xi Huang, Shanshan Zhang, Fanglin Niu, Yongri Ouyang, Zhexing Shou, Jikui Liu

Published in: International Journal of Clinical Oncology | Issue 2/2019

Abstract

Background

CYP3A4 is a major enzyme catalyzing the metabolism of endogenous steroids that play an important role in the etiology of carcinogenesis. This study was designed to investigate the contribution of CYP3A4 polymorphism to breast cancer in Chinese Han female population.

Methods

To examine whether variants of CYP3A4 contribute to breast cancer, 5 single-nucleotide polymorphisms (SNPs) of CYP3A4 were genotyped by Sequenom MassARRAY in 267 breast cancer patients and 302 healthy controls. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression adjusted for age.

Results

We found that the TT genotype of CYP3A4*1G (rs2242480) polymorphism was associated with increased risk of breast cancer using the fixed effects model (recessive model: OR = 2.34, p = 0.018). Stratified according to age, CYP3A4*1G increased the risk of breast cancer especially in less than 50-year-old group (codominant model OR = 3.68, p = 0.041; recessive model: OR = 3.55, p = 0.012). Furthermore, TT genotype of rs2242480 was associated with Cerb-B2 positive (recessive model: OR = 2.47, p = 0.025) and stage I/II (recessive model: OR = 2.32, p = 0.041). However, no statistically significant associations in other polymorphisms and haploview analysis were observed.

Conclusions

This study provides an evidence for polymorphism of CYP3A4 gene associated with the development of breast cancer, also a new insight into etiology of breast cancer. However, the underlying mechanism of the CYP3A4 gene in breast cancer is necessary for further study.

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistic, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed

Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefPubMed

Fasching PA, Ekici AB, Adamietz BR et al (2011) Breast cancer risk—genes, environment and clinics. Geburtsh Frauenheilk 71(12):1056–1066CrossRefPubMed

Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014CrossRefPubMedCentralPubMed

Easton DF, Bishop DT, Ford D et al (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52(4):678–701PubMed

Dai ZJ, Liu XH, Ma YF et al (2016) Association between single nucleotide polymorphisms in DNA polymerase kappa gene and breast cancer risk in Chinese Han population: a STROBE-compliant observational study. Medicine 95(2):e2466CrossRefPubMed

Xia P, Li B, Geng T et al (2014) FGFR2 gene polymorphisms are associated with breast cancer risk in the Han Chinese population. Am J Cancer Res 5(5):1854–1861

Zhou L, He N, Feng T et al (2014) Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China. Am J Cancer Res 5(8):2467–2475

Modugno F, Knoll C, Kanbourshakir A et al (2003) A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 82(3):191–197CrossRefPubMed

10.

Lee AJ, Cai MX, Thomas PE et al (2003) Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144(8):3382–3398CrossRefPubMed

11.

Capdevila J, Falck J, Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41(2):163–181PubMed

12.

Yang X, Zhang B, Molony C et al (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20(8):1020–1036CrossRefPubMed

13.

Murray GI, Patimalla S, Stewart KN et al (2010) Profiling the expression of cytochrome P450 in breast cancer. Histopathology 57(2):202–211CrossRefPubMed

14.

Mitra R, Guo Z, Milani M et al (2011) CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem 286(20):17543–17559CrossRefPubMed

15.

Rebbeck TR, Troxel AB, Walker AH et al (2007) Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomark Prev 16(3):444–450CrossRef

16.

Russo J, Hasan LM, Balogh G et al (2003) Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 87(1):1–25CrossRefPubMed

17.

Bozina N, Bradamante V, Lovrić M (2009) Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arhiv Za Higijenu Rada I Toksikologiju 60(2):217–242CrossRefPubMed

18.

Eshragh J, Dhruva A, Paul SM et al (2017) Associations between neurotransmitter genes and fatigue and energy levels in women after breast cancer surgery. J Pain Symptom Manag 53(1):67–84 e67CrossRef

19.

Gabriel S, Ziaugra L, Tabbaa D (2009) SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. https://doi.org/10.1002/0471142905.hg0212s60 CrossRefPubMed

20.

Thomas RK, Baker AC, Debiasi RM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39(3):347–351CrossRefPubMed

21.

Brockstedt U, Krajinovic M, Richer C et al (2002) Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res Genet Toxicol Environ Mutagen 516(1–2):41–47CrossRef

22.

Hormones TE, Group BCC (2011) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 105(5):709–722

23.

Nithipatikom K, Brody DM, Tang AT et al (2010) Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci 101(12):2629–2636CrossRefPubMed

24.

Keshava C, Mccanlies EC, Weston A (2004) CYP3A4 polymorphisms—potential risk factors for breast and prostate cancer: a huge review. J Urol 160(9):825–841

25.

Lamba JK, Lin YS, Schuetz EG et al (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271–1294CrossRefPubMed

26.

Du J, Xing Q, Xu L et al (2006) Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7(6):831–841CrossRefPubMed

27.

Tabor HK, Risch NJ, Myers RM (2002) Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 3(5):391–397CrossRefPubMed

28.

He BX, Shi L, Qiu J et al (2011) A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol 108(3):208–213CrossRef

29.

Yang W, Zhao D, Han S et al (2015) CYP3A4*1G regulates CYP3A4 intron 10 enhancer and promoter activity in an allelic-dependent manner. Int J Clin Pharmacol Ther 53(8):647–657CrossRefPubMed

30.

Chau CH, Price DK, Till C et al (2015) Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS One 10(5):e0126672CrossRefPubMed

31.

Pascual T, Apellaniz-Ruiz M, Pernaut C et al (2017) Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS One 12(7):e0180192CrossRefPubMed

32.

Fiszer-Maliszewska L, Laczmanski L, Dolinska A et al (2018) Polymorphisms of ABCB1, CYP3A4 and CYP3A5 genes in ovarian cancer and treatment response in poles. Anticancer Res 38(3):1455–1459PubMed

33.

Parada H Jr, Steck SE, Cleveland RJ et al (2017) Genetic polymorphisms of phase I metabolizing enzyme genes, their interaction with lifetime grilled and smoked meat intake, and breast cancer incidence. Ann Epidemiol 27(3):208–214CrossRefPubMed

34.

Johnson N, Walker K, Gibson LJ et al (2012) CYP3A variation, premenopausal estrone levels, and breast cancer risk. J Natl Cancer Inst 104(9):657–669CrossRefPubMed

35.

Leong SPL, Shen ZZ, Liu TJ et al (2010) Is breast cancer the same disease in asian and western countries? World J Surg 34(10):2308–2324CrossRefPubMed

36.

Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2):S8–S15CrossRefPubMed

Title: Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population
Authors: Xu Liu
Xi Huang
Shanshan Zhang
Fanglin Niu
Yongri Ouyang
Zhexing Shou
Jikui Liu
Publication date: 01-02-2019
Publisher: Springer Singapore
Published in: International Journal of Clinical Oncology / Issue 2/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1346-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Low-dose Gamma Knife radiosurgery plus whole-brain radiation therapy for patients with 5 or more brain metastases with or without meningeal dissemination

Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients

Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City

Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer

Current status of projects for developing cancer-related clinical practice guidelines in Japan and recommendations for the future

Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer